Teva slips as 2025 earnings outlook misses estimates
JHVEPhoto/iStock Editorial via Getty Images Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after
JHVEPhoto/iStock Editorial via Getty Images Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after
Teva Pharmaceutical press release (NYSE:TEVA): Q4 Non-GAAP EPS of $0.71 beats by $0.01. Revenue of
Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q4 earnings results on Wednesday, January 29th, before
JHVEPhoto The U.S. FDA has added a boxed warning to the labeling of Teva Pharmaceutical
JHVEPhoto/iStock Editorial via Getty Images Teva Pharmaceutical Industries’ (NYSE:TEVA) U.S. division has sued CMS over
JHVEPhoto/iStock Editorial via Getty Images Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with
Samsung Bioepis and Teva Pharmaceutical (NYSE:TEVA) announced that the companies have entered into a license,
Chris Ryan Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached
hapabapa/iStock Editorial via Getty Images Novo Nordisk (NOVO) is petitioning the FDA to exclude its
iQoncept A weekly summary of insider trading highlighting notable buying and selling by investors, directors